NASDAQ: EDSA · Life Sciences · 4 alerts · CIK 1540159
Share price
$1.89Close, Nov 16
Market cap
$18.2M
Shares outstanding
9.64MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Edesa Biotech, Inc. filings on SEC EDGAR ↗
Edesa Biotech announced that the European Commission has granted orphan designation to its investigational drug paridiprubart for the treatment of Acute Respiratory Distress Syndrome (ARDS). The designation provides regulatory incentives including reduced development fees and potential market exclusivity for up to 10 years following approval.
Edesa Biotech granted Kyorin Pharmaceutical an exclusive license to develop and commercialize its anti-TLR4 monoclonal antibody, paridiprubart (EB05), for the treatment of ARDS in Japan. Edesa receives a $12 million upfront payment and is eligible for up to $134 million in development, regulatory, and sales milestones, plus tiered double-digit royalties. Kyorin will fund all development and commercialization activities in Japan while Edesa retains rights in all other territories.